Electromed, Inc. Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2019. The source is an annual Form 10-K, not a standalone 2018 fourth-quarter filing; quarterly results are not separately presented in the provided text.
Business Context
Electromed develops, manufactures and sells SmartVest high-frequency chest wall oscillation airway-clearance systems for patients with compromised pulmonary function. Revenue is generated primarily through a direct-to-patient and provider model, with additional institutional and international sales.
- Primary product: SmartVest SQL, with SmartVest Connect wireless technology.
- Primary markets: U.S. home care, institutional settings and international distributors.
- U.S. revenue was approximately 95% home care and 5% hospital sales.
- The company had 119 employees and 40 field sales employees at June 30, 2019.
Financial Performance and Liquidity
| Metric | Fiscal 2019 | Fiscal 2018 | Change |
|---|---|---|---|
| Net revenue | $31.300 million | $28.307 million | +10.6% |
| Gross profit | $23.848 million | $21.773 million | +9.5% |
| Gross margin | 76.2% | 76.9% | Down 70 basis points |
| Operating income | $2.819 million | $2.712 million | +3.9% |
| Net income | $1.969 million | $1.831 million | +7.5% |
| Diluted earnings per share | $0.23 | $0.21 | +9.5% |
| Operating cash flow | $2.590 million | $2.442 million | +6.0% |
- Home care revenue increased 10.3% to $28.949 million, primarily from more referrals per field sales employee, a larger sales force and improved referral approval rates.
- Institutional revenue increased 3.4% to $1.604 million.
- International revenue increased 49.4% to $747,000, although international expansion is not a primary strategic focus.
- SG&A increased 8.7% to $20.446 million, driven primarily by higher compensation, sales incentives and share-based compensation.
- R&D expense increased to $583,000, or 1.9% of revenue, from $251,000, or 0.9%.
- Cash increased to $7.808 million from $7.456 million. Working capital was approximately $20.919 million.
- Capital expenditures were $1.331 million, including $1.090 million spent on a facility expansion.
- The company had no outstanding balance on its revolving credit line and no remaining term-loan debt at June 30, 2019.
- The revolving credit facility provides up to $2.5 million, subject to borrowing-base limitations, and expires December 18, 2019 if not renewed.
Material Changes Versus Fiscal 2018
- Revenue growth was led by domestic home care sales and improved referral conversion.
- Gross margin declined modestly because of lower institutional selling prices.
- Net income increased despite higher payroll, R&D and depreciation expenses.
- Fiscal 2018 included a one-time approximately $406,000 medical device excise-tax refund, which reduced SG&A; the refund was received in July 2018.
- Fiscal 2019 included approximately $151,000 of accelerated amortization related to terminating a leased office facility.
- The term loan matured and was repaid in December 2018 with a cash payment of approximately $1.085 million.
- The Aerobika OPEP distribution arrangement was discontinued in November 2018.
- The company adopted ASC 606 using the full retrospective method. Fiscal 2018 revenue was recast to $28.307 million, and retained earnings increased by approximately $0.8 million as of July 1, 2017.
Guidance, Outlook and Management Commentary
Management’s fiscal 2020 priorities are profitable revenue growth, improved referral quality and reimbursement rates, and maintaining high standards of integrity, respect and privacy. Planned growth initiatives include:
- Increasing referrals in adult pulmonology and bronchiectasis.
- Improving sales productivity and clinic penetration.
- Expanding clinical evidence supporting SmartVest use in bronchiectasis.
- Enhancing patient and provider support.
- Developing next-generation product features, including SmartVest Connect with Bluetooth technology and supporting mobile applications.
- Growing the institutional market and using selected HME distributors in targeted U.S. geographies.
Management expects R&D spending as a percentage of revenue to remain relatively consistent with fiscal 2019 and believes long-term gross margins should be slightly below 80%, subject to reimbursement and product-mix fluctuations. The company expects cash flows from operations or available borrowings to fund equipment purchases and completion of the facility expansion, estimated at $1.5 million to $1.7 million in total.
Risks, Contingencies and Unusual Items
- Revenue depends substantially on Medicare, Medicaid and private insurance reimbursement. Reimbursement rates, coverage policies, appeals and patient payment capacity can materially affect collections and reported revenue.
- ASC 606 requires estimates of variable consideration for installment payments, payer appeals, deductibles, coinsurance and copayments. Actual collections could differ from estimates and cause revenue reversals.
- The revolving credit facility must be renewed by December 18, 2019 to remain available. It contains financial covenants, including a minimum tangible net worth of $10.125 million, and restricts additional debt and dividends.
- Competition includes Hill-Rom/Advanced Respiratory, Philips/RespirTech and International Biophysics, as well as alternative airway-clearance therapies.
- The company faces FDA, international medical-device, quality-system, privacy, fraud-and-abuse and advertising compliance requirements.
- The medical device excise-tax moratorium was scheduled to end December 31, 2019. The company expected the SmartVest to remain eligible for the retail exemption, but future tax treatment should be verified.
- The company provides lifetime warranties for qualifying U.S. and Canadian home-care systems and three-year warranties for institutional and most international sales. The warranty reserve was $810,000 at June 30, 2019.
- The facility expansion was expected to be completed in the first quarter of fiscal 2020.
- The filing reports no material pending litigation and no off-balance-sheet arrangements.
Most Important Facts to Verify
- Whether the revolving credit facility was renewed after its December 18, 2019 expiration date and on what terms.
- Subsequent reimbursement trends, payer mix and collections relative to ASC 606 contract-asset estimates.
- Fiscal 2020 adoption and impact of the new lease-accounting standard.
- Completion cost and timing of the New Prague facility expansion.
- Commercial launch and adoption of SmartVest Connect Bluetooth and mobile applications.
- Whether gross margins, referral conversion and home-care growth continued without relying on favorable reimbursement assumptions.
- Actual effect of the medical device excise-tax moratorium expiration and the company’s claimed retail exemption.
- Future warranty claims, inventory obsolescence related to the phased-out SV2100 product and patent expirations.